DelveInsight’s, “Small Cell Lung Cancer – Pipeline Insight, 2021,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

    Geography Covered
    • Global coverage

    Small Cell Lung Cancer Understanding
    Small Cell Lung Cancer: Overview
    Small cell lung cancer accounts only for 13% of the lung cancers. However, SCLC is the more aggressive form of lung cancer. With SCLC, the cancer cells tend to grow quickly and travel to other parts of the body, or metastasize, more easily. Small cell lung cancer is more strongly linked to smoking. Small cell lung cancer typically have had relatively very few symptoms. The symptoms can result from local growth of the tumor, spread to nearby areas, distant spread, paraneoplastic syndromes, or a combination thereof. SCLC diagnosis begins with a thorough physical examination and medical history. When SCLC reaches the extensive stage, treatment is aimed at relieving symptoms, not at curing the disease.

    "Small Cell Lung Cancer - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Small Cell Lung Cancer pipeline landscape is provided which includes the disease overview and Small Cell Lung Cancer treatment guidelines. The assessment part of the report embraces, in depth Small Cell Lung Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.


    Report Highlights
    ? The companies and academics are working to assess challenges and seek opportunities that could influence Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Small Cell Lung Cancer.

    Small Cell Lung Cancer Emerging Drugs Chapters
    This segment of the Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
    Small Cell Lung Cancer Emerging Drugs
    ? HLX-10: Henlix Biotech
    HLX10 in combination with chemotherapy can be potentially used for the treatment of metastatic esophageal squamous-cell carcinomas (mESCC), squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), gastric cancer (GC) and cervical cancer (CC). Currently the patient enrollment has started in phase III for the treatment of extensive small cell lung cancer.

    ? Tiragolumab: Genentech
    Tiragolumab (anti-TIGIT, MTIG7192A, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). Clinical trials for Tiragolumab are being conducted by Genentech for the treatment of patients with small cell lung cancer.

    ? Tislelizumab: BeiGene
    Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to Fc?R on macrophages. Tislelizumab was designed to bind to PD?1, a cell surface receptor that plays an important role in allowing tumor cells to evade the immune system. Tislelizumab is in phase III clinical trials for small cell lung cancer.

    ? Lucitanib: Haihe Bipharma
    Lucatinib is an oral small molecule TKI targeting FGFR1-3, VEGFR1-3, PDGFR ?/?, with significant efficacy and high safety Rapid oral absorption being studied in phase II/III for the treatment of small cell lung cancer.

    ? LP002: Taizhou HoudeAoke Biomedical Co., Ltd.
    LP002 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. LP002 clinical trials are being conducted in phase II for the treatment of Small cell lung cancer.

    ? LY 01610: Luye Pharma Group, Ltd
    LY01610 is a DNA topoisomerase inhibitor being developed by Luye Pharma for the treatment of patients with small cell lung cancer.
    Further product details are provided in the report??..

    Small Cell Lung Cancer: Therapeutic Assessment
    This segment of the report provides insights about the different Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:
    ? Major Players in Small Cell Lung Cancer
    There are approx. 200+ key companies which are developing the therapies for Small Cell Lung Cancer. The companies which have their Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. phase III include, Henlix Biotech
    ? Phases
    DelveInsight’s report covers around 200+ products under different phases of clinical development like
    • Late stage products (Phase III)
    • Mid-stage products (Phase II)
    • Early-stage product (Phase I) along with the details of
    • Pre-clinical and Discovery stage candidates
    • Discontinued & Inactive candidates

    ? Route of Administration
    Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
    • Oral
    • Subcutaneous
    • Intravenous
    • Intramuscular

    ? Molecule Type
    Products have been categorized under various Molecule types such as
    • Bispecific Antibody
    • Peptides
    • Small molecule
    • Gene therapy
    ? Product Type
    Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

    Small Cell Lung Cancer: Pipeline Development Activities
    The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.
    Pipeline Development Activities
    The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Small Cell Lung Cancer drugs.

    Small Cell Lung Cancer Report Insights
    • Small Cell Lung Cancer Pipeline Analysis
    • Therapeutic Assessment
    • Unmet Needs
    • Impact of Drugs

    Small Cell Lung Cancer Report Assessment
    • Pipeline Product Profiles
    • Therapeutic Assessment
    • Pipeline Assessment
    • Inactive drugs assessment
    • Unmet Needs

    Key Questions
    Current Treatment Scenario and Emerging Therapies:
    • How many companies are developing Small Cell Lung Cancer drugs?
    • How many Small Cell Lung Cancer drugs are developed by each company?
    • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Small Cell Lung Cancer?
    • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Small Cell Lung Cancer therapeutics?
    • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
    • What are the clinical studies going on for Small Cell Lung Cancer and their status?
    • What are the key designations that have been granted to the emerging drugs?